Share on StockTwits

Repros Therapeutics (NASDAQ:RPRX) was downgraded by Piper Jaffray to a “neutral” rating in a research note issued on Wednesday.

Repros Therapeutics (NASDAQ:RPRX) traded down 2.48% on Wednesday, hitting $21.61. The stock had a trading volume of 217,869 shares. Repros Therapeutics has a 52 week low of $12.61 and a 52 week high of $29.79. The stock has a 50-day moving average of $15.55 and a 200-day moving average of $16.75. The company’s market cap is $499.4 million.

Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Monday, August 11th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.37) by $0.01. On average, analysts predict that Repros Therapeutics will post $-1.53 EPS for the current fiscal year.

Separately, analysts at Ascendiant Capital Markets reiterated a “positive” rating on shares of Repros Therapeutics in a research note on Friday, August 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Repros Therapeutics has a consensus rating of “Buy” and a consensus price target of $35.00.

Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.

Receive News & Ratings for Repros Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.